Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 176

Similar articles for PubMed (Select 19480240)

1.

Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours.

Drake J, Shearwood AM, White J, Friis R, Zeps N, Charles A, Dharmarajan A.

Eur J Gynaecol Oncol. 2009;30(2):133-41.

PMID:
19480240
2.

Loss of beta-catenin is associated with poor survival in ovarian carcinomas.

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS.

Int J Gynecol Pathol. 2004 Oct;23(4):337-46.

PMID:
15381903
4.

Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.

Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, Saunders DN, Grygiel JJ, Sutherland RL, Henshall SM.

Prostate. 2007 Jul 1;67(10):1081-90.

PMID:
17476687
5.

Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.

Voutilainen KA, Anttila MA, Sillanpää SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma VM.

J Clin Pathol. 2006 May;59(5):460-7. Epub 2006 Feb 3.

6.

Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type.

Yamamoto S, Tsuda H, Honda K, Kita T, Takano M, Tamai S, Inazawa J, Yamada T, Matsubara O.

Mod Pathol. 2007 Dec;20(12):1278-85. Epub 2007 Sep 14.

7.

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.

Jacob F, Ukegjini K, Nixdorf S, Ford CE, Olivier J, Caduff R, Scurry JP, Guertler R, Hornung D, Mueller R, Fink DA, Hacker NF, Heinzelmann-Schwarz VA.

PLoS One. 2012;7(2):e31885. doi: 10.1371/journal.pone.0031885. Epub 2012 Feb 21.

8.

Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro.

Horvath LG, Henshall SM, Kench JG, Saunders DN, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Clin Cancer Res. 2004 Jan 15;10(2):615-25.

9.
10.

Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.

Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damião R, Gomes TS, Gonçalves WJ.

Oncol Rep. 2009 Feb;21(2):313-20.

PMID:
19148501
11.

beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients.

Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM, Danielsen HE.

Eur J Cancer. 2005 May;41(8):1127-34. Epub 2005 Apr 14.

PMID:
15911235
12.

Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells.

Carmon KS, Loose DS.

Mol Cancer Res. 2008 Jun;6(6):1017-28. doi: 10.1158/1541-7786.MCR-08-0039.

13.

beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma.

Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH.

Gynecol Oncol. 2003 Mar;88(3):363-8.

PMID:
12648588
14.

Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas.

Hrzenjak A, Tippl M, Kremser ML, Strohmeier B, Guelly C, Neumeister D, Lax S, Moinfar F, Tabrizi AD, Isadi-Moud N, Zatloukal K, Denk H.

J Pathol. 2004 Sep;204(1):19-27.

PMID:
15307134
15.

Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.

Vartiainen J, Lassus H, Lehtovirta P, Finne P, Alfthan H, Butzow R, Stenman UH.

Int J Cancer. 2008 May 1;122(9):2125-9.

PMID:
18098286
16.

The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.

Ford CE, Jary E, Ma SS, Nixdorf S, Heinzelmann-Schwarz VA, Ward RL.

PLoS One. 2013;8(1):e54362. doi: 10.1371/journal.pone.0054362. Epub 2013 Jan 11.

17.

Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.

Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B.

Int J Gynecol Pathol. 2009 May;28(3):211-21. doi: 10.1097/PGP.0b013e31818b0f5e.

PMID:
19620938
18.

Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.

Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS.

Pathology. 2009;41(4):366-71. doi: 10.1080/00313020902884451.

PMID:
19404850
19.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD.

Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.

20.

Immunoexpression of beta-catenin--E-cadherin complex in primary serous ovarian tumors.

Stawerski P, Wagrowska-Danilewicz M, Stasikowska O, Gottwald L, Danilewicz M.

Pol J Pathol. 2008;59(1):27-32.

PMID:
18655368
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk